OFF time Archives

Conceptual Serina Therapeutics laboratory illustration with neurons, drug-delivery imagery and a display highlighting a potential 2027 clinical milestone.

Serina Therapeutics: A Parkinson’s Bet Where Delivery Is the Message -( $ABBV $SER )

by John F. Heerdink, Jr. October 26, 2026 250Views 0Likes

As SER-252 advances into its second dose cohort, Serina is building a case that improving how a medicine reaches patients can be as consequential as discovering the medicine itself. Serina Therapeutics, Inc. (NYSE American: SER) is pursuing an appealing proposition in biotechnology:…

AbbVie’s JUVMO Approval Puts Parkinson’s Innovation Back in Motion And Serina Therapeutics Has a Timely Opening -( $ABBV $AMRX $SER $SUPN $IBB $XBI )

by John F. Heerdink, Jr. September 29, 2026 629Views 0Likes

AbbVie Inc. (NYSE: ABBV) has secured (Sept. 28) FDA approval for JUVMO™ (tavapadon), a new once-daily Parkinson’s therapy, adding an important fresh option to a market long defined by the delicate art of managing motor symptoms, “OFF” time, dyskinesia and medication burden. For Serina…

Serina Therapeutics: A Parkinson’s Story Where Better Drug Delivery Could Become the Main Event -( $PFE $SER $XBI )

by John F. Heerdink, Jr. September 8, 2026 359Views 0Likes

Serina Therapeutics, Inc. (NYSE American: SER) is building a potentially compelling clinical and platform-driven story around a familiar biotech proposition: take a medicine with demonstrated utility, improve the way it behaves in the body, and create a product patients may find meaningfully…

Tag: OFF time

Serina Therapeutics: A Parkinson’s Bet Where Delivery Is the Message -( $ABBV $SER )

AbbVie’s JUVMO Approval Puts Parkinson’s Innovation Back in Motion And Serina Therapeutics Has a Timely Opening -( $ABBV $AMRX $SER $SUPN $IBB $XBI )

Serina Therapeutics: A Parkinson’s Story Where Better Drug Delivery Could Become the Main Event -( $PFE $SER $XBI )

Your Guide To Staying Informed In The Markets